These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 18263593)
1. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593 [TBL] [Abstract][Full Text] [Related]
2. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899 [TBL] [Abstract][Full Text] [Related]
3. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma. Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510 [TBL] [Abstract][Full Text] [Related]
4. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972 [TBL] [Abstract][Full Text] [Related]
5. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114 [TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537 [TBL] [Abstract][Full Text] [Related]
8. Targeting of the protein interaction site between FAK and IGF-1R. Zheng D; Kurenova E; Ucar D; Golubovskaya V; Magis A; Ostrov D; Cance WG; Hochwald SN Biochem Biophys Res Commun; 2009 Oct; 388(2):301-5. PubMed ID: 19664602 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316 [TBL] [Abstract][Full Text] [Related]
11. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T Mol Cancer; 2005 Oct; 4():37. PubMed ID: 16209712 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models. Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459 [TBL] [Abstract][Full Text] [Related]
13. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Jaquish DV; Yu PT; Shields DJ; French RP; Maruyama KP; Niessen S; Hoover H; A Cheresh D; Cravatt B; Lowy AM Carcinogenesis; 2011 Aug; 32(8):1151-6. PubMed ID: 21565828 [TBL] [Abstract][Full Text] [Related]
14. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Zheng D; Golubovskaya V; Kurenova E; Wood C; Massoll NA; Ostrov D; Cance WG; Hochwald SN Mol Carcinog; 2010 Feb; 49(2):200-9. PubMed ID: 19885860 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. Golubovskaya V; Beviglia L; Xu LH; Earp HS; Craven R; Cance W J Biol Chem; 2002 Oct; 277(41):38978-87. PubMed ID: 12167618 [TBL] [Abstract][Full Text] [Related]
16. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. Karnevi E; Said K; Andersson R; Rosendahl AH BMC Cancer; 2013 May; 13():235. PubMed ID: 23663483 [TBL] [Abstract][Full Text] [Related]
17. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128 [TBL] [Abstract][Full Text] [Related]
18. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Zhang J; He DH; Zajac-Kaye M; Hochwald SN Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573 [TBL] [Abstract][Full Text] [Related]
19. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785 [TBL] [Abstract][Full Text] [Related]
20. Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. Vu HA; Beppu Y; Chi HT; Sasaki K; Yamamoto H; Xinh PT; Tanii T; Hara Y; Watanabe T; Sato Y; Ohdomari I J Biomed Biotechnol; 2010; 2010():290516. PubMed ID: 21318151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]